Skip to main content
OpenTrials
Completed

NCT Number: NCT05900752

A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients

The goal of this interventional clinical study is to study whether the consumption of QiMeiYan Probiotics in 25-35 young people with Mild irritable bowel syndrome (IBS Score 75 - 175) will reduce the frequency of Diarrhea.

140 eligible participants (70 males and 70 females) will be enrolled in two study sites and randomly assigned to two groups of products QiMeiYan Probiotics and placebo. All participants will consume assigned products once a day after meals and record the critical data such as photo of feces. Three site visits will be arranged and all clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis.

Researchers will compare the two groups to validate if the daily consumption of QiMeiYan Probiotics will reduce the frequency of Diarrhea in the study population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ai'er Hospital, Shanghai, Shanghai Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chinese males or females, age between 25-35, the ratio is 1:1;
  • Mild irritable bowel syndrome diagnosed by IBS-SSS, IBS Score 75 - 175;
  • Subjects agree not to take any other probiotics during the trial;
  • Willing not to participate in other interventional clinical studies during the period of this trial;
  • Fully understand the purpose, benefits obtained, possible risks and side effects of the study;
  • Willing to comply with all research requirements and procedures;
  • Understand the test procedure, read, and sign an appropriate Informed Consent Form indicating their willingness to participate.

Exclusion criteria

  • In the treatment of gastrointestinal symptoms;
  • Lactose intolerance;
  • Suffering from other organic diseases currently that affect the intestinal function, such as history, colon or rectal cancer resection of gastrointestinal tract, inflammatory bowel disease, diabetes, thyroid function hyperfunction or decline, congenital megacolon, scleroderma, anorexia, etc.;
  • Controlling diet, exercising more, or taking medications to control weight or affect appetite in the last 3 months;
  • Subjects have any of the following medical history or have been clinically examined to have the following diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases;
  • Abuse alcohol or other drugs, supplement or OTC drugs currently or in the past may cause bowel dysfunction or can affect test result evaluation;
  • Take drugs frequently that may affect gastrointestinal function or the immune system according to PI's judgment;
  • Use laxatives or other substances that promote digestion 2 weeks before the trial;
  • Take dairy products or other foods containing prebiotics/bacteria 10 days before the trial.

Treatment and study plan

QiMeiYan Probiotics

Dietary Supplement

consume one sachet of the assigned product, once a day after meals.

Placebo product

Dietary Supplement

consume one sachet of the assigned product, once a day after meals.

Primary outcomes

  1. Frequency of Diarrhea in IBS-D Patients

    Time frame: baseline day 0, day 28

    Frequency of Diarrhea in IBS-D Patients for the two groups of participants during the study period

Secondary outcomes

  1. Change of Score of IBS-SSS

    Time frame: baseline day 0, day14, day 28

    Change of Score of IBS-SSS for the two groups of participants during the study period. The score of 75-175 is defined as mild severity, 175-300 as middle level severity and >300 as serious level.

  2. Change of Bristol Stool Scale of the feces

    Time frame: baseline day 0, day 7, day 14, day 21, day 28

    Change of Bristol Stool Scale (1-7) of the feces for the two groups of participants during the study period. There are 7 types of feces that matches the look and form of bowel movements indicating potential diarrhea or constipation.

Sponsors and collaborators

Lead sponsor

Shenzhen Precision Health Food Technology Co. Ltd.,

Other Gov

Registry information

Official study title

A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients: A Two-Center, Randomized, Double-Blind, Placebo-controlled Study

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jun 13, 2023
Registry last updated
Nov 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.